Tuesday, 21 January 2020

Rectovaginal Fistula Market 2019 Global Industry Key Players, Share, Trend, Segmentation and Forecast to 2023

Global Rectovaginal Fistula Market Research Report: by Diagnosis (Physical Exam, Contrast Tests, Blue Dye Test, Computerized Tomography (CT) Scan) By Treatment (Medications, Surgery) By End User (Hospitals & Clinics, Diagnostic Centers) - Forecast Till 2023
Market Scenario
As per the Birth Injury Guide, estimates show that between 700 and 900 women die every year due to pregnancy or childbirth-related complications in United States.
Additionally, the growing research and development expenditure by the government as well as private sector is likely to contribute to the market growth. However, the high cost of surgery may restraint the market growth during the assessment period.  
Due to increasing focus on research and development in treatment of diseases, moreover increasing applications in cancer treatment are the factors responsible to boost the market growth during assessment period. Companies are using a trend of strategic alliance and acquisition to gain the market and minimize the competition in the market.
The Global Rectovaginal Fistula Market held a market value of USD 950 million in 2017 and is projected to grow at a CAGR of 5.4% over the forecast period. 
Key players
Some of the prominent players in the global rectovaginal fistula market are Cook Medical, Takeda Pharmaceutical Company, Johnson & Johnson Services Inc., Pfizer Inc., Allergan, AbbVie Inc, Novartis International AG, Bayer AG, Bristol-Myers Squibb, Boehringer Ingelheim GmbH, F. Hoffmann-La Roche, Eli Lilly and Company, GlaxoSmithKline plc, Sanofi S.A, and others
Segmentation
The global rectovaginal fistula market has been segmented into diagnosis, treatment, and end user.
Based on treatment, the market has been segmented into medications and surgery. Medications is further segmented into antibiotics and infliximab. Surgery is further segmented into sewing an anal fistula plug or patch of biologic tissue into the fistula, using a tissue graft, repairing the anal sphincter muscles, performing a colostomy before repairing a fistula in complex or recurrent cases.
By diagnosis, the market has been segmented into physical exam, contrast tests, blue dye test, computerized tomography (CT) scan, magnetic resonance imaging (MRI), anorectal ultrasound, anorectal manometry, and others.
The rectovaginal fistula market, by end user, has been segmented into hospitals & clinics, diagnostic centres, academic institutions and research organizations, and others.
The global rectovaginal fistula market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The rectovaginal fistula market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.         
The European rectovaginal fistula market has been segmented into Western Europe and Eastern Europe. The Western Europe rectovaginal fistula market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.      
The rectovaginal fistula market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The rectovaginal fistula market in the Middle East & Africa has been segmented into the Middle East and Africa.       
Regional Market Summary
On regional basis, the Americas is anticipated to dominate the global rectovaginal fistula market owing to the growing R&D budgets by both government as well as commercial pharmaceutical and biotechnological companies and increasing adoption of advanced technologies in the region.  Europe is expected to hold the second largest position in the global rectovaginal fistula market owing to the presence of strong academic & research base and availability of funding for research in the European countries. Asia Pacific has served an opportunity for rectovaginal fistula market in this region due to increasing demand for the better treatment and devices and increasing prevalence of disease like cancer. The Middle East & Africa has the least share of the global rectovaginal fistula market. Moreover, the major market share of the region is expected to be held by the Middle East region owing to the increasing government initiatives for the healthcare sector.   
Browse More Healthcare Reports @

Monday, 20 January 2020

Pedicle Screw Systems Market Size, Emerging Technologies, Future Trends, Competitive Analysis and Segments Poised for Strong Growth in Future 2023

Global Pedicle Screw Systems Market: Information by Surgery Type (Open, Minimally Invasive), Product Type (Polyaxial Pedicle Screw, Others), Indication (Spinal Trauma, Others), Application (Thoracolumbar Fusion, Others), End User — Forecast till 2023
Market Scenario:
Pedicle screw system are the instruments that are used in spinal surgery to stop the pain caused by joints owing to disease. These screws are used in the lumbar spine for more complex anatomy such as the thoracic and thoracolumbar level. The pedicle screw allows stability in spinal arthrodesis and provide three column control over the spinal elements for improving deformation.
The Global Pedicle Screw Systems Market is accounted for USD 506.65 million in 2017 and expected to register ~ 6.3 % CAGR during the forecast period (2018–2023).
The rising prevalence of arthritis, increasing incidence of spinal cord injuries, aging population, and growing preference of minimally invasive surgeries are expected to drive the growth of the market. Moreover, rising R&D spending and aggressive strategies adopted by the top players such as new product launches are contributing to the growth of the market. For instance, in September 2018, Nvision Biomedical Technologies, LLC launched the pedicle screw system focus at North American Spine Society (NASS).
The high cost associated with pedicle screw systems, Sluggish product approval processes and strict regulatory frameworks may hamper the growth of the market during the assessment period.
Segmentation:
The Global Pedicle Screw Systems Market has been segmented on the basis of surgery type, product type, indication, application, and end user.
On the basis of surgery type, the market has been classified as open surgery and minimally invasive surgery. The market, by product type, has been segmented into polyaxial pedicle screw systems, monoaxial pedicle screw systems, and others. Based on indication, the market has been segmented into spinal degeneration, spinal trauma, spinal deformities, and others. The market, by application, has been segmented into thoracolumbar fusion and spinal cervical fusion. On the basis of end user, the market has been classified as hospitals and clinics, research organization and academic institute, and others. The polyaxial pedicle screw systems segment is expected to hold the largest market share of the pedicle screw systems market, by product type, during the forecast period. Also, minimally invasive surgery to register the highest CAGR in the global pedicle screw systems market during the forecast period.
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The pedicle screw systems market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European pedicle screw systems market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
The pedicle screw systems market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The pedicle screw systems market in the Middle East & Africa has been segmented into the Middle East and Africa.
Regional Market Summary:
The Americas are likely to dominate the global pedicle screw systems market owing to the rising prevalence of spinal disorders, increasing geriatric population, and rising in FDA approved pedicle screws. According to the report published by Centers for Disease Control and Prevention (CDC), in 2016, 5.1% of men of 65 years and over are suffering with lumbar spine in United States. Also, 24.5% of women 65 years of age and over have lumbar spine in United States.
The European market is expected to be the second-largest pedicle screw systems market. The market growth in this region can be attributed to the government support for research & development and availability of funds for research.
Asia-Pacific is expected to be the fastest-growing pedicle screw systems market during the forecast period owing to the rising number of the orthopedic surgeries, rising investments in healthcare and expansions by market players in the region. Moreover, country such as India and China are considering fastest growing region due to the presence of huge patient population. Moreover, the government of these countries are open to adopt new technology, and best treatment option from a developed country. According to the report published by OMICS International, in 2017, around 500,000 to 600,000 spinal surgery had performed in China.
The market in the Middle East & Africa is expected to account for the smallest share of the global pedicle screw systems market due to an underdeveloped healthcare sector, lack of technical knowledge, and poor medical facilities.
Key Players:
Some of the key players in the global pedicle screw systems market are Alphatec Spine, Inc., Amedica Corporation, B. Braun Melsungen AG, Depuy Synthes, Globus Medical, Inc., K2M Group Holdings, Inc., Medtronic PLC, Nvision Biomedical Technologies, LLC., Orthofix International N.V., RTI Surgical, Inc., SeaSpine, Stryker Corporation, Zimmer Biomet Holdings, Inc.
Browse More Healthcare Reports @

Global Oncology Information Systems Market 2019 Study and Analysis Research Report Forecast To 2023

Global Oncology Information Systems Market Research Report: by Product & Service Type (Software, Professional Services), Application (Medical Oncology, Radiation Oncology, Surgical Oncology), End User (Hospitals & Oncology Clinics) - Forecast Till 2023
Market Scenario
Global Oncology Information Systems (OIS) Market is expected to register a healthy CAGR over the forecast period. The market held a market value of USD 2,356.6 million in 2017 and is projected to grow at a CAGR of 7.5% during the forecast period.
Oncology Information Systems (OIS) is a comprehensive information and image management solution that facilitates the management of patient treatment schedules, treatment plans, treatment delivery, and treatment summaries. This system involves the exchange of information between radiation therapy departments and the healthcare enterprises. Factors attributed for the market growth are worldwide growing geriatric population along with rising prevalence of cancer, increasing investments in cancer research, and technological advancements in OIS. The International Agency for Research on Cancer (IARC) stated that there were 14 million new cases of cancer in 2012 that grew to 17.0 million in 2018, which is anticipated to reach to more than 22 million by 2030. Progress in developing treatments is enabling investors to invest in oncology research. Increasing equity investments in ca ncer-therapeutics startups is foreseen to shape the OIS vertical in the near future. On the contrary, higher costs associated with OIS services are anticipated to restrain the market growth over the forecast period.
Segmentation
The global oncology information systems market has been segmented into product & service type, application, and end user.
By product & service type, the market has been segmented into software and professional services. The software segment is further categorized into patient information systems and treatment planning systems. The professional services segment is further divided into consulting/optimization services, implementation services, and post-sale & maintenance services. The software for patient information systems segment spearheaded the market in 2017 as these systems offer advantages including planned treatment and remote access due to digital availability as compared to conventional record maintenance methods.
On the basis of application, the market has been classified into medical oncology, radiation oncology, and surgical oncology. The medical oncology segment would lead the market over the forecast period owing to rising applications of OIS in efficiently managing, interpreting, analyzing, and storing the patient information, as well as, in predicting the treatment results for patients, thereby improving their survival rates.
Based on end user, the market has been categorized into hospitals & oncology clinics, government institutes, and research centers.
The global oncology information systems market has been segmented by region into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The oncology information systems market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European oncology information systems market has been segmented into Western Europe and Eastern Europe. The Western Europe oncology information systems market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
The oncology information systems market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The oncology information systems market in the Middle East & Africa has been segmented into the Middle East and Africa.
Key players
Accuray Incorporated, Cerner Corporation, Philips Healthcare, McKesson Corporation, Altos Solutions, Inc., Elekta AB, Varian Medical Systems, Inc., Flatiron Health, Inc., RaySearch Laboratories, Epic Systems Corporation, Bogardus Medical Systems, Inc., and CureMD Healthcare are some of the prominent players in the global oncology information systems market.
Regional Analysis
Geographically, the Americas would grab the highest market share over the forecast period due to the presence of oncology information systems providers, changing lifestyle coupled with rising burden of cancer, increasing expenditure on healthcare, and adoption of oncology information systems in the US and Canada. The IARC reported that in 2018, the Americas have 13.3% of the global population and accounted for 21.0% of incidence and 14.4% of mortality worldwide.
Asia-Pacific would represent the phenomenal growth during the forecast period due to growing elderly population coupled with rising prevalence of cancer. The World Health Organization (WHO) and IARC reported that the proportions of cancer deaths in Asia (57.3%) are higher than the proportions of incident cases (48.4%) due to the higher frequency of certain cancer types associated with poorer prognosis and higher mortality rates.
The oncology information systems market in the Middle East & Africa will exhibit considerable market growth rate from 2018 to 2023. Majority of the regional market is likely to govern by the Middle East region due to the presence of world-class cancer treatment centers in Dubai, Saudi Arabia, increasing healthcare sector reforms, and gradually rising investments in OIS sector.
Growing adoption of OIS in European countries, namely, UK, Germany, France, Italy, and Spain, as the major market value contributors such as Philips Healthcare, Elekta AB, and RaySearch Laboratories are headquartered in the region.
Browse More Healthcare Reports @

Global Biochips Market Analysis 2019 Forecasts to 2023

An expert on premium research reports, Market Research Future has added a report titled "Global Biochips Market 2023" to its offering. The report provides an in-depth analysis by by Type (DNA Chips, Lab-On-A-Chip, and Protein Chips), by Technology (Microarrays, and Microfluidics) By End User (Biotechnology and Pharmaceutical Companies, Hospitals and Diagnostics Centers)-Forecast Till 2023
Global Biochips Market held a market value of USD 7,300 million in 2017, according to the MRFR. The market is expected to exhibit a strong 16.6% CAGR over the forecast period from 2018 to 2023, according to the report.
Biochips are intended to function in biological environment, preferably inside living organism. The factors such as increasing technological advancements in biochips is the major driving factor for the market. Moreover, increasing adoption of personalized medicine, as personalised medicine has many applications in cancer genomics. Furthermore, growing applications of biochips will boost the market growth during forecast period. For instance, biochips can perform thousands of biological reactions operations in few seconds.  
However, high cost of the instruments and stringent regulatory guidelines may restrain the growth of the market.
According to national Cancer Institute, in 2018, an estimated 1,735,350 new cases of cancer were diagnosed in the United States and 609,640 people may die from the disease.
Competitive Landscape:Perkinelmer, Inc., Fluidigm Corporation, Agilent Technologies, Inc., Abbott Laboratories, Bio-Rad Laboratories Inc., Cepheid Inc., Illumina, Inc., GE Healthcare, Thermo Fisher Scientific, Inc, Roche Diagnostics are some of the prominent players in the global biochips market.
Segmentation:The Global Biochips Market has been segmented into type, technology, and end user.
By type, the market has been segmented into DNA chips, lab-on-a-chip, protein chips, cell arrays, and tissue arrays. DNA chips is further segmented into gene expression, SNP genotyping, cancer diagnosis & treatment, genomics, drug discovery, agricultural biotechnology, and others. Lab-on-a-chip is further segmented into clinical diagnostics, genomics, IVD (In-Vitro Diagnostic) & POC (Point of care), Proteomics, Drug Discovery, and others. Protein chips is further segmented into proteomics, expression profiling, diagnostics, high-throughput screening, drug discovery, others.
Based on technology, the market has been segmented into microarrays and microfluidics.
The biochips market, by end user, has been segmented into biotechnology and pharmaceutical companies, hospitals and diagnostics centers, academic & research institutes, and others.
Regional Market Summary
Geographically, the Americas is anticipated to dominate the global biochips market owing to the high domestic income, and presence of major market players. Moreover, increasing patient population in US. According to American Cancer Society, the overall estimate of 1,735,350 cases for 2018 equals more than 4,700 new cancer diagnoses each day.
Europe is expected to hold the second largest position in the global biochips market. The market growth in this region is attributed to the presence of strong academic & research base and availability of funding for research in the European countries. For instance, the European Research Council (ERC) provides grants for technological and scientific research conducted within the European Union (EU).
The biochips market in Asia-Pacific region consists of countries namely China, Japan, Republic of Korea, India, Australia and Rest of Asia-Pacific. The Asia-Pacific region is expected to be fastest growing region owing to increasing government focus on biomedical and biotechnology sector and growing number of target population in the region.  
The Middle East & Africa has the lowest share of the global biochips market. Majority of the market of the region is anticipated to be held by the Middle East region owing to the growing government initiatives for the healthcare sector.  
Browse More Healthcare Reports @

Global Cranial Fixation and Stabilization Market Trends, Demand and Forecast to 2025

The Global Cranial Fixation and Stabilization Market is expected to reach USD 2.29 Billion by 2025, registering a CAGR of 8.90%.
This cranial fixation and stabilization devices market growth can be attributed to the growing healthcare market and the ever-expanding technology market. Advances in these fields have created an environment that is conducive to the development of specialized surgical procedures for traditionally high-risk surgeries.
According to the UN, globally, one in six individuals suffers from a neurological disorder. There are several invasive surgeries that being developed to treat such conditions, requiring cranial fixation and stabilization equipment.
SEGMENTATION
By Category
Cranial stabilization equipment is used to secure the head during surgery, while cranial fixation implements are tools required to maintain the structural stability of the head and neck.
  • Cranial Fixation Systems: Cranial fixation covers a wide array of tools and implements such as meshes, flap tube clamps, plates, and screws to be used during surgery. They are used predominantly for affixing bones, securing skin, and enhancing cranial integrity post-surgeries such as craniotomies.
  • Cranial Stabilization Systems: Cranial surgeries are usually very delicate and complex, necessitating the use of equipment to immobilize the head. This is accomplished by the use of cranial stabilization equipment such as skull clamps and horseshoe headrests.
By Product
  • Meshes: The leading market segment as 48% of all cranial injuries are maxillofacial. Over 52% of road accident-related injuries are mandibular fractures that require meshes.
  • Skull Clamps: Ideal for prolonged surgeries that require patient immobilization for long periods with limited soft tissue damage. Used to hold the head firmly in place during surgery.
  • Flap Tube Clamps: Used to attach cranial bones to the cranium during delicate surgeries when only a singular motion can be performed upon the afflicted area.
  • Horseshoe Headrests: Used in cases where head movement is not to be completely restrained and soft tissue damage needs to be minimized.
  • Plates: Used to seal gaping cranial wounds.
  • Screws: Facilitate the attachment of cranial bones.
  • Accessories: Include patient positioning systems and support systems.
By Type
  • Resorbable: Materials that are eventually broken down by the body. The growth of the segment is limited by the high costs of the equipment.
  • Non-Resorbable: These are biocompatible and offer unparalleled rigidity and stability to the cranium. Used extensively in developing countries due to their low costs.
By End User
  • Hospitals: The segment commands the largest share of the global cranial fixation and stabilization market as most cranial surgeries are performed in hospitals. Cranial surgeries require the latest equipment and amenities, along with a high level of expertise, which are offered by hospitals.
  • Ambulatory Surgical Centers: As emergency and temporary patient-stabilization surgeries are performed at these centers, the segment accounts for a small market share, which is somewhat offset by the higher revenue per surgery generated.
  • Others: This segment includes on-site trauma and emergency surgeries. This is a niche segment with growth potential due to the establishment of trauma centers at industrial complexes.
 By Region
  • Americas: Largest regional market, with North America accounting for 55% of the global market share.
  • Asia-Pacific: Fastest growing regional market
  • Europe: Second-largest market
  • Middle East & Africa
Key Players
  • Johnson & Johnson (US)
  • Stryker (US)
  • Ostomed (UK)
  • KLS Martin Group (Germany)
  • Medtronic (US)
  • Integra LifeSciences Corporation (US)
  • Braun Melsungen AG (Germany)
  • Changzhou Huida (China)
  • DePuy Synthes (US)
  • Evonos (Germany)
  • Jeil Medical (South Korea)
  • Medicon (Germany)
  • Micromar (Brazil)
  • NEOS Surgery (Spain)
  • Pro Med Instruments (Germany)
  • Zimmer Biomet (US)

Analysis of Over-The-Wire Micro-Guide Catheter Market in Global Industry: Technology, Applications, Growth and Status 2019

Market Highlights
Over-the-wire Micro Guide Catheter (OTW Micro Guide Catheter) is a thin tubular Medical device inserted into the body for diagnosis or treatments of diseases like cardiovascular, neurovascular, and urology. Specially designed to ease complex procedures, OTW Micro Guide Catheter combining excellent cross-ability and optimal guide-wire support, can effectively treat challenging cases involving tortuous vessels, CTO (chronic total occlusions), bifurcations, and highly stenosed and calcified lesions, giving the high success rate.
OTW Catheters are widely used in cardiovascular applications such as peripheral and coronary interventions and neurovascular interventional applications. The high success rate associated with the use of these catheters further augments its uptake and demand, resultantly driving its market growth.
According to Market Research Future (MRFR), the global Over-the-wire Micro Guide Catheters market Size is expected to grow at a CAGR of 9.37% during the forecast period (2018–2023).
According to reports published by the Centers for Disease Control and Prevention, the coronary heart disease is the most common type of heart diseases that accounted for the death of about 366,000 people in 2015.
Over-the-wire catheters comparatively make a better choice to treat a brain aneurysm than the rapid exchange catheters owing to their capabilities of extra pushing to enter stenose vessels, and additional support that they provide.
The increasing occurrences of coronary heart diseases, neurovascular diseases, hypertension, and other metabolic disorders, raising awareness for health, advancement in technologies, good healthcare infrastructure, and favorable reimbursement policies are fueling the market growth. 
Regional Analysis
The global over-the-wire micro guide catheters market is segmented into four regions: the Americas, Europe, Asia Pacific, and the Middle East & Africa. Americas is the global market leader for over-the-wire Micro-guide catheters. As per the study published in the Surgical Neurology International in 2017, it was found that more than 3% population of the United States equivalent to nearly 10 million individuals have a brain aneurysm. North America commands for the major share of the market whereas; South America show the fastest growth of the market due to the presence of boundless growth opportunities.
Europe OTW Micro Guide Catheter market holds the second position, globally. This is primarily attributable to the increasing prevalence of obesity as well as the increased incidence rate of hypertension and diabetes, which in turn is escalating cardiovascular traumas and cardiac arrest. Each year 15% of deaths in Europe occur due to cardiovascular diseases claims a study conducted by European Society of Cardiology.
The Asia Pacific region is the fastest growing market for the over-the-wire micro guide catheters. The region presents significant growth opportunities for market players as local policy makers continue to restructure the policy framework for the healthcare sector.
Global OTW Micro Guide Catheter Market: Segmentation
The global over-the-wire micro guide catheters market is segmented on the basis of applications and end-users. On the basis of applications, it is segmented into cardiovascular and neurovascular. By the cardiovascular, it is segmented into angiography, angioplasty, peripheral stenting, and others. On the basis of the neurovascular, it is segmented into intracranial aneurysms, percutaneous neurointerventional procedures, and others. Based on end-user the market is segmented into hospitals & clinics, ambulatory surgical centers, research & academic institutes, and others.  
Major Players in the Over-the-wire Micro Guide Catheters Market
Enki – Microtubes, Cardinal Health, DePuy Synthes, Koninklijke Philips N.V, Penumbra Inc., Terumo Europe N.V., Integer Holdings Corporation, Merit Medical Systems Inc., Teleflex Incorporated, Cook Medical, Boston Scientific Corporation, Asahi Intecc Company Limited, and Medtronic plc.

Herbal Medicine Market 2019 World Analysis and Forecast to 2023

Herbal Medicine Market Analysis 2019 to 2023 report published by “Market Research Future”. According to report Global Herbal Medicine Market to Rise At 5.88% CAGR by 2023. Herbal Medicine Industry report anlayzes Herbal Medicine Market for Category (Herbal Pharmaceuticals, Herbal Functional Foods, Herbal Beauty Products and Herbal Dietary Supplements), by Type of Medicinal Plants (Marrubium Vulgare, Vaccinium Macrocarpon, Echinacea, Curcuma Longa, Camellia Sinensis, Actaea Racemose, Aloe Vera, Zingiber Officinale, Cocos Nucifera, Cinnamomum Spp and Allium Sativum), by Form (Extracts, Powders, Capsules & Tablets and Syrups), by Source (Leaves, Root & Barks, Whole Plants and Fruits), by Distribution Channel and by Region and Forecast till 2023
Herbal Medicines are becoming increasingly popular among modern consumers. Market Research Future (MRFR) projects that the Global Herbal Medicine Market will capture a CAGR of 5.88% between 2018 and 2023. Whereas it is also anticipated to generate a revenue of around USD 111 billion by the end of the projection period.
The Global Herbal Medicine Market Size is expected to register a CAGR of 5.88% to reach USD 1,29,689.3 million by 2023.
Herb is a plant or plant part used for its scent, flavor, or therapeutic properties. Herbal medicines are a type of dietary supplements. They are sold as tablets, capsules, powders, teas, extracts, and fresh or dried plants. People use herbal medicines to maintain and improve their health. Many conventional drugs originate from plant sources, and most of the few effective drugs are plant-based. Examples include aspirin (from willow bark), digoxin (from foxglove), quinine (from cinchona bark), and morphine (from the opium poppy). The development of drugs from plants continues, with drug companies engaged in the large-scale pharmacologic screening of herbs.
Key Players
The prominent players in the global herbal medicine market are Arkopharma, Bayer AG, BEOVITA, Hishimo Pharmaceuticals, Schaper & Brümmer, ZeinPharma Germany GmbH, Venus Pharma GmbH, Dasherb Corp, and Arizona Natural Products among other.
Some of the key strategies followed by the players operating in the global herbal medicine market were innovation, product development, acquisition, and expansion.
Market Dynamics
Herbal medicines are used since ancient times for numerous health conditions. It is the oldest and most extensively used system of medicine in the world today. There are various kinds of herbal medicines and supplements used across the world. According to the National Center for Biotechnology Information, 2015, the World Health Organization (WTO), reported that around 70% to 80% of people globally rely on herbal sources for their treatment. Also, according to the American Botanical Council, September 2017, it was reported that in 2016, the sale of herbal supplements increased by 7.7% in the US. It was also estimated that consumers spending on herbal supplements increased to USD 7.452 billion in 2016. Thus, the increase in the demand for herbal products for healthcare purposes is likely to enhance this market during the forecast period.
Segmentation
The global herbal medicine Market, by category, is segmented into herbal pharmaceuticals, herbal dietary supplements, herbal functional foods, and herbal beauty products. The herbal pharmaceutical segment led the herbal medicine market with USD 50,972.4 million in 2017. The herbal pharmaceutical segment is growing owing to the increasing research and development on various herbs to find their medicinal properties, growing demand for natural medicines having fewer side-effects, and rising prevalence of chronic diseases such as diabetes, arthritis, cancer, sleep disorders, and digestive problems.
Marrubium vulgare segment is the fastest-growing segment of the market at CAGR of 6.45% during the forecast period. Marrubium vulgare also known as white horehound is a largely cultivated plant, and its above-ground parts are used for medicinal use. The upper part of the plant is used in powder, liquid extract, or juice form for medicinal purposes. Marrubium vulgare is largely used for digestion problems which include indigestion, loss of appetite, gas, bloating, diarrhea, constipation, and gallbladder complaints. It is also used for the treatment of breathing problems
The global herbal medicine Market, by form, is segmented into extracts, powders, capsules and tablets, syrups, and others. The extracts segment accounted for the largest market share of 36.95% in 2017.
The global herbal medicine Market, by source, is segmented into leaves, fruit, roots, and barks whole plant, and others (combinations of various plant parts). On the basis of source, the leaves segment is expected to lead the global herbal medicine market. The leaves segment held a share of USD 51,495.2 million in 2017.
The global herbal medicine Market, by distribution channel, is segmented into hospital and retail pharmacies, e-commerce, and others. The hospital & retail pharmacies segment accounted for the largest market share of 55.82% in 2017. The growing prevalence of cancer and infectious diseases across the globe, improving healthcare infrastructure, and skilled professionals are driving the growth of hospital and retail pharmacies in the herbal medicine market.
Regional Analysis
Europe is expected to account for the largest market share owing to extensive R&D for herbal medicine, increasing funding for research on medicinal plants, and growing preference for herbal drugs globally. On a regional basis, Europe is segmented into Western Europe and Eastern Europe. Western Europe is estimated to lead market growth during the forecast period. The increasing prevalence of chronic diseases and rising government support facilitate market growth within the region.
Americas accounts for the second largest share in the global herbal medicine market. It accounted for a considerable market share of 16.2% as of 2017. The use of herbal medicines is also growing in the US after conducting the first national study of alternative and complementary medicines used by Eisenberg et al. According to the National Center for Biotechnology Information 2017, it was reported that herbal supplements were majorly used for conditions such as cancer (43.1%), stroke (48.7%), and arthritis (43%) in the US. Such a high demand and preference for herbal products is likely to boost the market growth during the forecast period.
Asia-Pacific is expected to register a CAGR of 5.99% during the forecast period owing to the adoption of traditional medicines by pharmaceutical companies, researchers, and policymakers. On the other hand, the Middle East and Africa are expected to observe a slow growth due to less awareness and in-depth knowledge about herbal drugs in this region.